Xeris Biopharma Holdings (XERS) Return on Capital Employed (2021 - 2026)
Xeris Biopharma Holdings' (XERS) quarterly Return on Capital Employed came in at 13.34% in Q1 2026, up 2337.0% YoY from 0.55% in Q1 2025, and up 43.19% on a QoQ basis from 9.31% in Q4 2025.
Xeris Biopharma Holdings (XERS) Return on Capital Employed (2021 - 2026) Analysis & Trends
Xeris Biopharma Holdings (XERS) has 6 years of Return on Capital Employed data on file, last reported at 13.34% in Q1 2026.
- Quarterly Return on Capital Employed rose 2337.0% year-over-year to 13.34% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 13.34% (up 2337.0% YoY) and the FY2025 annual result came in at 10.22%, up 2534.0% from the prior year.
- Return on Capital Employed climbed to 13.34% in Q1 2026, from 9.31% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 13.34% in Q1 2026 to a low of 50.09% in Q1 2022.
- A 5-year average of 18.91% and a median of 19.13% in 2023 frame the typical range for Return on Capital Employed.
- Annual changes were most pronounced in 2022 — Return on Capital Employed surged 5023 bps — and 2024, when it jumped 127 bps.
- Tracing XERS's Return on Capital Employed over 5 years: stood at 32.76% in 2022, then jumped by 42 bps to 19.13% in 2023, then gained by 21 bps to 15.18% in 2024, then soared by 161 bps to 9.31% in 2025, then jumped by 43 bps to 13.34% in 2026.
- The last three Return on Capital Employed figures came in at 13.34% (Q1 2026), 9.31% (Q4 2025), and 4.15% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 6.60% |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 17.16% |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 6.07% |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 22.04% |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | -0.29% |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 18.67% |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 5.52% |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Xeris Biopharma Holdings | 1.48 Bn | 1.36 Bn | 79.59 Mn | 17.23% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 17.23% |
| Mar 31, 2026 | 13.34% |
| Dec 31, 2025 | 9.31% |
| Sep 30, 2025 | 4.15% |
| Jun 30, 2025 | -4.27% |
| Mar 31, 2025 | -10.03% |
| Dec 31, 2024 | -15.18% |
| Sep 30, 2024 | -19.19% |
| Jun 30, 2024 | -14.37% |
| Mar 31, 2024 | -17.53% |
| Dec 31, 2023 | -19.13% |
| Sep 30, 2023 | -20.45% |
| Jun 30, 2023 | -25.76% |
| Mar 31, 2023 | -26.30% |
| Dec 31, 2022 | -32.76% |
| Sep 30, 2022 | -47.49% |
| Jun 30, 2022 | -45.76% |
| Mar 31, 2022 | -50.09% |
| Dec 31, 2021 | -82.98% |